Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis
Abstract Atherosclerosis and atherothrombosis, the major contributors to cardiovascular diseases (CVDs), represent the leading cause of death worldwide. Current pharmacological therapies have been associated with side effects or are insufficient at halting atherosclerotic progression effectively. Pi...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2022-02-01
|
| Series: | Journal of Nanobiotechnology |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s12951-022-01279-y |
| _version_ | 1817994493508452352 |
|---|---|
| author | Haikun Liu Geoffrey Pietersz Karlheinz Peter Xiaowei Wang |
| author_facet | Haikun Liu Geoffrey Pietersz Karlheinz Peter Xiaowei Wang |
| author_sort | Haikun Liu |
| collection | DOAJ |
| description | Abstract Atherosclerosis and atherothrombosis, the major contributors to cardiovascular diseases (CVDs), represent the leading cause of death worldwide. Current pharmacological therapies have been associated with side effects or are insufficient at halting atherosclerotic progression effectively. Pioneering work harnessing the passive diffusion or endocytosis properties of nanoparticles and advanced biotechnologies in creating recombinant proteins for site-specific delivery have been utilized to overcome these limitations. Since CVDs are complex diseases, the most challenging aspect of developing site-specific therapies is the identification of an individual and unique antigenic epitope that is only expressed in lesions or diseased areas. This review focuses on the pathological mechanism of atherothrombosis and discusses the unique targets that are important during disease progression. We review recent advances in site-specific therapy using novel targeted drug-delivery and nanoparticle-carrier systems. Furthermore, we explore the limitations and future perspectives of site-specific therapy for CVDs. Graphical Abstract |
| first_indexed | 2024-04-14T01:52:39Z |
| format | Article |
| id | doaj.art-9a8c89d188eb4ebb96e0f94b9d3e97bd |
| institution | Directory Open Access Journal |
| issn | 1477-3155 |
| language | English |
| last_indexed | 2024-04-14T01:52:39Z |
| publishDate | 2022-02-01 |
| publisher | BMC |
| record_format | Article |
| series | Journal of Nanobiotechnology |
| spelling | doaj.art-9a8c89d188eb4ebb96e0f94b9d3e97bd2022-12-22T02:19:15ZengBMCJournal of Nanobiotechnology1477-31552022-02-0120112310.1186/s12951-022-01279-yNanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosisHaikun Liu0Geoffrey Pietersz1Karlheinz Peter2Xiaowei Wang3Molecular Imaging and Theranostics Laboratory, Baker Heart and Diabetes InstituteAtherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes InstituteAtherothrombosis and Vascular Biology Laboratory, Baker Heart and Diabetes InstituteMolecular Imaging and Theranostics Laboratory, Baker Heart and Diabetes InstituteAbstract Atherosclerosis and atherothrombosis, the major contributors to cardiovascular diseases (CVDs), represent the leading cause of death worldwide. Current pharmacological therapies have been associated with side effects or are insufficient at halting atherosclerotic progression effectively. Pioneering work harnessing the passive diffusion or endocytosis properties of nanoparticles and advanced biotechnologies in creating recombinant proteins for site-specific delivery have been utilized to overcome these limitations. Since CVDs are complex diseases, the most challenging aspect of developing site-specific therapies is the identification of an individual and unique antigenic epitope that is only expressed in lesions or diseased areas. This review focuses on the pathological mechanism of atherothrombosis and discusses the unique targets that are important during disease progression. We review recent advances in site-specific therapy using novel targeted drug-delivery and nanoparticle-carrier systems. Furthermore, we explore the limitations and future perspectives of site-specific therapy for CVDs. Graphical Abstracthttps://doi.org/10.1186/s12951-022-01279-yAntibodiesAtherosclerosisGene deliveryNanoparticlesTargeted drug deliveryThrombosis |
| spellingShingle | Haikun Liu Geoffrey Pietersz Karlheinz Peter Xiaowei Wang Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis Journal of Nanobiotechnology Antibodies Atherosclerosis Gene delivery Nanoparticles Targeted drug delivery Thrombosis |
| title | Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis |
| title_full | Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis |
| title_fullStr | Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis |
| title_full_unstemmed | Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis |
| title_short | Nanobiotechnology approaches for cardiovascular diseases: site-specific targeting of drugs and nanoparticles for atherothrombosis |
| title_sort | nanobiotechnology approaches for cardiovascular diseases site specific targeting of drugs and nanoparticles for atherothrombosis |
| topic | Antibodies Atherosclerosis Gene delivery Nanoparticles Targeted drug delivery Thrombosis |
| url | https://doi.org/10.1186/s12951-022-01279-y |
| work_keys_str_mv | AT haikunliu nanobiotechnologyapproachesforcardiovasculardiseasessitespecifictargetingofdrugsandnanoparticlesforatherothrombosis AT geoffreypietersz nanobiotechnologyapproachesforcardiovasculardiseasessitespecifictargetingofdrugsandnanoparticlesforatherothrombosis AT karlheinzpeter nanobiotechnologyapproachesforcardiovasculardiseasessitespecifictargetingofdrugsandnanoparticlesforatherothrombosis AT xiaoweiwang nanobiotechnologyapproachesforcardiovasculardiseasessitespecifictargetingofdrugsandnanoparticlesforatherothrombosis |